DSpace Repository

Synthesis, molecular docking, and QSAR study of sulfonamide-based indoles as aromatase inhibitors

Show simple item record

dc.contributor.author Pingaew R.
dc.contributor.author Mandi P.
dc.contributor.author Prachayasittikul V.
dc.contributor.author Prachayasittikul S.
dc.contributor.author Ruchirawat S.
dc.contributor.author Prachayasittikul V.
dc.date.accessioned 2021-04-05T03:21:50Z
dc.date.available 2021-04-05T03:21:50Z
dc.date.issued 2018
dc.identifier.issn 2235234
dc.identifier.other 2-s2.0-85033552512
dc.identifier.uri https://ir.swu.ac.th/jspui/handle/123456789/12927
dc.identifier.uri https://www.scopus.com/inward/record.uri?eid=2-s2.0-85033552512&doi=10.1016%2fj.ejmech.2017.10.057&partnerID=40&md5=eedc5b18d0eeabd0844d07d1c860d3f6
dc.description.abstract Thirty four of indoles bearing sulfonamides (11–44) were synthesized and evaluated for their anti-aromatase activities. Interestingly, all indole derivatives inhibited the aromatase with IC50 range of 0.7–15.3 μM. Indoles (27–36) exerted higher aromatase inhibitory activity than that of ketoconazole. The phenoxy analogs 28 and 34 with methoxy group were shown to be the most potent compounds with sub-micromolar IC50 values (i.e., 0.7 and 0.8 μM, respectively) without affecting to the normal cell line. Molecular docking demonstrated that the indoles 28, 30 and 34 could occupy the same binding site on the aromatase pocket and share several binding residues with those of the natural substrate (androstenedione), which suggested the competitive binding could be the mode of inhibition of the compounds. The most potent analog 28 could mimic H-bond interactions of the natural androstenedione with MET374 and ASP309 residues on the aromatase. QSAR model also revealed that the para-phenoxy indole (28) affords the higher value of electronegativity descriptor MATS6e as well as the higher inhibitory activity compared with that of the ortho-phenoxy compound (34). The study highlighted a series of promising indoles to be potentially developed as novel aromatase inhibitors for therapeutics. © 2017 Elsevier Masson SAS
dc.subject 4 bromo n [2 (1h indol 3 yl)ethyl]benzenesulfonamide
dc.subject 4 fluoro n [2 (1h indol 3 yl)ethyl]benzenesulfonamide
dc.subject 4 trifluoromethyl n [2 (1h indol 3 yl)ethyl]benzenesulfonamide
dc.subject androstenedione
dc.subject aromatase
dc.subject aromatase inhibitor
dc.subject aspartic acid
dc.subject ellipticine
dc.subject indole derivative
dc.subject ketoconazole
dc.subject letrozole
dc.subject methionine
dc.subject n,n' [(2,2' [(4 nitrophenyl)methylene]bis(1h indole 3,2 diyl)]bis(ethane 2,1 diyl)]bis(4 bromobenzenesulfonamide)
dc.subject n,n' [(2,2' [(4 nitrophenyl)methylene]bis(1h indole 3,2 diyl)]bis(ethane 2,1 diyl)]bis(4 fluorobenzenesulfonamide)
dc.subject n,n' [[2,2' [(4 bromophenyl)methylene]bis(1h indole 3,2 diyl)]bis(ethane 2,1 diyl)]bis(4 trifluoromethylbenzenesulfonamide)
dc.subject n,n' [[2,2' [(4 cyanophenyl)methylene]bis(1h indole 3,2 diyl)]bis(ethane 2,1 diyl)]bis(4 chlorobenzenesulfonamide)
dc.subject n,n' [[2,2' [(4 cyanophenyl)methylene]bis(1h indole 3,2 diyl)]bis(ethane 2,1 diyl)]bis(4 fluorobenzenesulfonamide)
dc.subject n,n' [[2,2' [(4 cyanophenyl)methylene]bis(1h indole 3,2 diyl)]bis(ethane 2,1 diyl)]bis(4 trifluoromethylbenzenesulfonamide)
dc.subject n,n' [[2,2' [(4 fluorophenyl)methylene]bis(1h indole 3,2 diyl)]bis(ethane 2,1 diyl)]bis(4 bromobenzenesulfonamide)
dc.subject n,n' [[2,2' [(4 fluorophenyl)methylene]bis(1h indole 3,2 diyl)]bis(ethane 2,1 diyl)]bis(4 chlorobenzenesulfonamide)
dc.subject n,n' [[2,2' [(4 fluorophenyl)methylene]bis(1h indole 3,2 diyl)]bis(ethane 2,1 diyl)]bis(4 trifluoromethylbenzenesulfonamide)
dc.subject n,n' [[2,2' [(4 hydroxyphenyl)methylene]bis(1h indole 3,2 diyl)]bis(ethane 2,1 diyl)]bis(4 trifluoromethylbenzenesulfonamide)
dc.subject n,n' [[2,2' [(4 nitrophenyl)methylene]bis(1h indole 3,2 diyl)]bis(ethane 2,1 diyl)]bis(4 trifluoromethylbenzenesulfonamide)
dc.subject n,n' [[2,2' [(4 trifluoromethylphenyl)methylene]bis(1h indole 3,2 diyl)]bis(ethane 2,1 diyl)]bis(4 bromobenzenesulfonamide)
dc.subject n,n' [[2,2' [(4 trifluoromethylphenyl)methylene]bis(1h indole 3,2 diyl)]bis(ethane 2,1 diyl)]bis(4 chlorobenzenesulfonamide)
dc.subject n,n' [[2,2' [(4 trifluoromethylphenyl)methylene]bis(1h indole 3,2 diyl)]bis(ethane 2,1 diyl)]bis(4 trifluoromethylbenzenesulfonamide)
dc.subject n,n' [[2,2' [(9 ethyl 9h carbazol 3 yl)methylene]bis(1h indole 3,2 diyl)]bis(ethane 2,1 diyl)]bis(4 chlorobenzenesulfonamide)
dc.subject n,n' [[2,2' [(9h fluoren 2 yl)methylene]bis(1h indole 3,2 diyl)]bis(ethane 2,1 diyl)]bis(4 chlorobenzenesulfonamide)
dc.subject sulfonamide
dc.subject unclassified drug
dc.subject aromatase inhibitor
dc.subject indole derivative
dc.subject sulfonamide
dc.subject animal cell
dc.subject Article
dc.subject binding competition
dc.subject controlled study
dc.subject drug binding site
dc.subject drug cytotoxicity
dc.subject drug mechanism
dc.subject drug potency
dc.subject drug protein binding
dc.subject drug screening
dc.subject drug synthesis
dc.subject enzyme active site
dc.subject enzyme inhibition
dc.subject hydrogen bond
dc.subject IC50
dc.subject molecular docking
dc.subject nonhuman
dc.subject quantitative structure activity relation
dc.subject animal
dc.subject cell survival
dc.subject chemical structure
dc.subject chemistry
dc.subject Chlorocebus aethiops
dc.subject dose response
dc.subject drug effects
dc.subject metabolism
dc.subject multivariate analysis
dc.subject synthesis
dc.subject Vero cell line
dc.subject Animals
dc.subject Aromatase
dc.subject Aromatase Inhibitors
dc.subject Cell Survival
dc.subject Cercopithecus aethiops
dc.subject Dose-Response Relationship, Drug
dc.subject Indoles
dc.subject Molecular Docking Simulation
dc.subject Molecular Structure
dc.subject Multivariate Analysis
dc.subject Quantitative Structure-Activity Relationship
dc.subject Sulfonamides
dc.subject Vero Cells
dc.title Synthesis, molecular docking, and QSAR study of sulfonamide-based indoles as aromatase inhibitors
dc.type Article
dc.rights.holder Scopus
dc.identifier.bibliograpycitation European Journal of Medicinal Chemistry. Vol 143, (2018), p.1604-1615
dc.identifier.doi 10.1016/j.ejmech.2017.10.057


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account

Statistics